01.19.26 -- Metrics, Not Audits, Should Lead Vendor Accountability

Advancing cell and gene therapies for rare pediatric diseases will require innovative trial strategies, early diagnosis, and improved treatment technologies.

Watch as our CGT experts explore the evolving landscape of viral vector manufacturing, overcoming production bottlenecks, and the strategies necessary to bring life-changing therapies to more patients.

Discover how Codex® HiCap RNA Polymerase optimizes mRNA yield while reducing dsRNA byproducts for safer, more effective therapeutics.

Economic volatility, regulatory uncertainty, and capacity constraints pose major risks to CDMOs, threatening growth, profitability, and long-term sustainability in an increasingly competitive global market.

Unlock the knowledge and strategies you need to navigate the complexities of CGT outsourcing and accelerate the success of your cell and gene therapy projects.

Learn how to navigate decision-making at critical steps and find solutions to key challenges in process development and scale-up to expedite oncolytic virus programs.

Industry 4.0 is revolutionizing CDMOs and CMOs. Find out how AI, IIoT, and automation are driving smarter, faster, and more compliant manufacturing to ensure agility, precision, and innovation.

Explore how a platform compares data to traditional qPCR, p24 ELISA, and TU assays in measuring both physical and functional titers.

Read how a manufacturing platform enabled the rapid production of lentiviral vector in eight months. Check out this strategy used to balance speed, risk mitigation, and the highest quality standards.

Specialized cell collection services depend on access to a large, diverse donor pool as well as robust donor screening and efficient collection practices.

Discover how our innovative rAAV production platform can revolutionize your gene therapy pipeline with unparalleled yield, quality, and scalability.